The latest news on the 2024 Mobosertinib/Mobosertinib Medicare Negotiations

Mobocertinib/Mobocertinib (Mobocertinib) The original drug has been launched in China, but it has not been included in medical insurance. For the latest medical insurance negotiation results, patients can pay attention to the official information released by the National Medical Insurance Bureau or relevant medical security agencies to keep abreast of the latest developments. At the same time, you can also search and understand relevant information through search engines or medical information platforms.

Mobosetinib is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are positive for epidermal growth factor receptor (EGFR) exon 20 insertion mutations and who have previously received platinum-based chemotherapy. In a single-arm phase I/II study, 28% of patients who had previously received platinum-based chemotherapy for metastatic non-small cell lung cancer positive for EGFR exon 20 insertion mutations achieved confirmed objective responses. Trials have shown that some patients taking moboxetinib survived for two years after receiving the breakthrough drug, well beyond the life expectancy of patients with this type of lung cancer.

The common domestic mobosetinib original drug, specification40mg*112 capsules per box, is priced at around RMB 40,000, which is very expensive, while theHong Kong clinical version specification40mg*30 capsules per box is priced at more than RMB 7,000 (the price may fluctuate due to exchange rates). Generic drugs of Mobotinib have also been put on the market for sale overseas. Its pharmaceutical ingredients are basically the same as those of the original drugs at home and abroad. For example, the production specifications of Laos Pharmaceutical Factory 40mg*120 pills per box may be more than 4,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.